Alexander Manganiello

Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX.

Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC.

Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA.

Icagen, Inc. engages in the development of pharmaceutical and drug discovery instruments. It offers chemistry, biology, and ion channels and transporters. The company was founded by Benjamin P. Warner and Frank Jeremiel Zimmerman in 1992 and is headquartered in Durham, NC.

Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

EraGen Biosciences, Inc. is a venture-backed biotechnology company. It designs, develops, manufactures and markets molecular diagnostic testing products and software for the research and clinical testing markets. The firm in-market and pipeline products, based on its novel, patented MultiCode platform chemistry, are the next generation of nucleic acid-based testing for the early detection and monitoring of cancer, genetic and infectious diseases. The company was founded in 1994 and is headquartered in Madison WI.

Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd

ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom.

eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA.

New Rhein Healthcare Investors LLC (New Rhein Healthcare Investors) is a private equity firm founded in 2010 by Parekh Greg. The firm is headquartered in Philadelphia, Pennsylvania.

Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York.

Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA.

Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018.

Merganser Biotech, Inc. engages in the development of of hepcidin mimetic peptides as new medicines for the treatment of hematological and iron overload diseases. The company was founded by Brian R. MacDonald and Gene Merutka in 2011 and is headquartered in Newtown Square, PA.